Latest in FDA approves Eli Lilly's weight loss drug Zepbound for sleep apnea, expanding use in U.S.
Sort by
1,481 items
-
FDA approves weight loss drug Zepbound for sleep apnea
Zepbound, Eli Lilly’s weight loss drug, can now be used to treat obstructive sleep apnea in adults with obesity, the FDA said.NBC News - 6h -
FDA approves Eli Lilly's weight loss drug Zepbound for sleep apnea, expanding use in U.S.
The agency's decision expands the use of Zepbound and could potentially pave the way for Eli Lilly to gain broader insurance coverage for the treatment.CNBC - 6h -
Eli Lilly given US approval to treat sleep disorder with weight-loss drug
Regulatory go-ahead marks latest boost for drugmaker’s blockbuster anti-obesity franchiseFinancial Times - 6h -
F.D.A. Approves Weight-Loss Drug to Treat Sleep Apnea
Zepbound is the first prescription drug approved specifically to treat the common condition.The New York Times - 7h -
FDA: Knockoff versions of Lilly obesity drug must come off the market
The federal government is phasing out off-brand copies of two blockbuster drugs used to treat obesity and diabetesABC News - 1d -
Ozempic parent’s stock having worst day since the 1980s as new weight-loss drug disappoints
Novo Nordisk’s stock dives as new weight loss drug disappoints in a late-stage trial, which gave a boost to Eli Lilly shares.MarketWatch - 14h -
Novo Nordisk shares tumble as weight-loss drug trial data disappoints
Obesity drug CagriSema misses goal of 25% body weight reductionFinancial Times - 17h -
FDA says Eli Lilly's weight loss drug Zepbound is no longer in shortage
The decision that will eventually bar compounding pharmacies from making unbranded versions of the injection.CNBC - 1d -
Weight Loss Drugs Changed Their Lives. Then They Lost Coverage.
In Michigan, the state’s largest insurer has tightened restrictions around medications like Wegovy. Patients are panicking.The New York Times - 1d -
FDA warns companies over unapproved weight loss drug sales
The Food and Drug Administration (FDA) said Tuesday in a statement it has sent warning letters to companies selling unapproved weight loss drugs. The letter went to Xcel Peptides, Swisschems, ...The Hill - 2d -
Merck to develop weight loss pill from Chinese drugmaker in up to $2 billion licensing deal
Merck will pay Hansoh $112 million upfront for rights to the drug, with the potential for an additional $1.9 billion in payments and royalties on sales.CNBC - 2d -
Tennessee woman accused of selling fake weight loss drugs as counterfeit concerns grow
A Tennessee woman was accused of selling counterfeit versions of popular weight loss drugs including Ozempic. Experts say fakes have exploded in the U.S.NBC News - 3d -
Russian lawmakers approve new bill expanding the definition of high treason
Russian lawmakers have approved a bill broadening the definition of high treason, which can bring a sentence of life in prisonABC News - 3d -
-
Why the investor craze for Ozempic and rival weight-loss drugs may resume next year
Novo Nordisk’s takeover of Catalent and the Danish firm’s push to launch a new generation of drugs could boost the importance of GLP agonists in 2025, Barclays analysts saidMarketWatch - 4d -
RFK Jr.’s Lawyer Has Asked the FDA to Revoke Polio Vaccine Approval
Aaron Siri, who specializes in vaccine lawsuits, has been at Robert F. Kennedy Jr.’s side reviewing candidates for top jobs at the Department of Health and Human Services.The New York Times - 5d -
RFK Jr.'s lawyer and top ally asked FDA to revoke approval of polio vaccine
Robert F. Kennedy Jr.’s personal attorney previously lobbied the Food and Drug Administration to revoke approval of the polio vaccine.ABC News - Dec. 13 -
In shift, RFK Jr. now says weight-loss drugs 'have a place'
His remarks come days before he holds confirmation meetings with GOP senators.ABC News - Dec. 12 -
Elon Musk contradicts RFK Jr.'s sentiments on weight loss drugs
Elon Musk validated the use of GLP-1 drugs in a post on X on Wednesday. But Robert F. Kennedy Jr. has said he's opposed to Americans using them to fight obesity.ABC News - Dec. 12 -
What other conditions could weight-loss drugs treat?
Initial research has focused on obesity, but Ozempic, Wegovy and Mounjaro may potentially be used for addiction, heart disease and Alzheimer’sFinancial Times - Dec. 12 -
Ro to offer lower-price vials of weight loss drug Zepbound by teaming up with Eli Lilly
It is made possible through a first-of-a-kind integration with Eli Lilly's direct-to-consumer website, and aims to streamline access to the popular treatment.CNBC - Dec. 11 -
The London Stock Exchange suffers another loss to the U.S.
The FTSE 100 equipment rental company said moving its primary listing to the U.S. increase it exposure to investors and allow for its inclusion in “premier U.S. equity indices.”MarketWatch - Dec. 10 -
Some health experts warn against microdosing weight loss drugs
The demand for weight loss drugs, like Ozempic and Wegovy, has skyrocketed in the past few years despite the high cost and unpleasant side effects for some people. The New York Times reports some ...CBS News - Dec. 9 -
The weight-loss drug boom has become one of the internet's biggest scams
As demand for obesity drugs like Wegovy, Zepbound, Mounjaro and Ozempic, outpaces supply, online scams are rising, according to cybersecurity experts.CNBC - Dec. 8 -
Do weighted blankets help you sleep better? Here's what to know
Weighted blankets are a popular choice to warm up in cold weather, but research on their effectiveness is limitedABC News - Dec. 7 -
U.S. drug store closures create pharmacy deserts
The closures of both independent and big chain drug stores across the U.S. has become a trend that is having a serious impact on health care. Mark Strassmann examines what is behind the change and ...CBS News - Dec. 5 -
Eli Lilly invests $3B to expand Wisconsin factory to help meet demand for Mounjaro, Zepbound
Eli Lilly is spending another $3 billion to bulk up manufacturing as the drugmaker seeks to stoke production of some blockbuster drugs and future productsABC News - Dec. 5 -
Weight-loss drug Mounjaro 'changed my life,' says mother-of-two
People struggling with their weight welcome the NHS rollout of Mounjaro but worry about delays.BBC News - Dec. 5 -
Prescription fills for weight loss drugs Zepbound and Wegovy more than doubled in 2024, GoodRx says
The jump in prescription fills comes despite limited insurance coverage and high out-of-pocket costs for Novo Nordisk's Wegovy and Eli Lilly's Zepbound.CNBC - Dec. 5 -
Millions will have to wait up to 12 years for NHS weight-loss drug
Fears that giving 3.4 million people immediate access to new weight-loss drug could overwhelm NHS.BBC News - Dec. 5 -
Eli Lilly Chief Says He Will Fight for the FDA, Challenging RFK Jr.’s Stance
The health care giant’s David Ricks defended the agency’s role in reviewing data and ensuring drug safety.The New York Times - Dec. 4 -
Will Trump nix Biden’s coverage plan for weight-loss drugs? It’ll be a close call.
While President-elect Donald Trump looks poised to scrap many policies of the Biden administration, one veteran analyst says it’s possible he could end up supporting the Democratic incumbent’s ...MarketWatch - Dec. 4 -
Zepbound brings more weight loss than Wegovy: Drugmaker
Adults who take Zepbound lose more weight than those who take competitor weight loss drug Wegovy, according to new clinical trial results. Zepound manufacturer Eli Lilly released results from their ...The Hill - Dec. 4 -
Eli Lilly's obesity drug beats rival in head-to-head trial — where Cramer sees shares going next
New trial data has cemented Club holding Eli Lilly's pole position in the highly competitive weight loss drug race.CNBC - Dec. 4 -
Eli Lilly says Zepbound’s weight-loss results beat those of rival Wegovy
Zepbound helped patients lose more weight than a major rival in a head-to-head trial.MarketWatch - Dec. 4 -
A rival weight loss drug to Wegovy helped people shed more pounds, study shows
People who took Zepbound, Eli Lilly’s weight loss drug, shed more pounds than those on Novo Nordisk’s Wegovy in a clinical trial, Lilly said in a release Wednesday.NBC News - Dec. 4 -
Eli Lilly's Zepbound causes greater weight loss than Novo Nordisk's Wegovy in head-to-head trial
Zepbound's greater weight loss is a huge advantage for Eli Lilly, which is competing with Novo Nordisk for a larger share of the weight loss drug market.CNBC - Dec. 4 -
Experts create controllable gastric balloon to aid weight loss
Device inflates before eating and contracts afterwards, simulating the effects of having a meal, say scientists. From weight loss jabs to vibrating pills , the obesity crisis has spawned myriad ...The Guardian - Dec. 3 -
Supreme Court hears arguments over FDA’s refusal to approve flavored e-cigarettes
Makers of flavored e-cigarettes brought various cases challenging the FDA’s decision to refuse approval and alleged the agency changed its standards of evaluation on short notice. NBC News’ ...NBC News - Dec. 3 -
US expands list of Chinese technology companies under export controls
The U.S. Commerce Department has expanded the list of Chinese technology companies subject to export controls to include many that make equipment used to make computer chipsABC News - Dec. 3
